M
NVO

MATAURO’s Novo Nordisk NVO Stock Holding History

MATAURO’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630K Buy
13,144
+3,061
+30% +$132K 0.08% 94
2026
Q1 		$371K Buy
+10,083
New +$478K 0.05% 103
2025
Q4 		– Sell
-47,076
Closed -$2.61M – 175
2025
Q3 		$2.61M Buy
47,076
+15,739
+50% +$921K 0.42% 39
2025
Q2 		$2.16M Buy
+31,337
New +$2.13M 0.41% 36

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

MATAURO's NVO Position: Q2 2026 in Review

MATAURO increased its Novo Nordisk (NVO) stake by 30% in Q2 2026, buying an estimated $132K and bringing the position to 13,144 shares worth $630K. The position accounts for 0.08% of the portfolio, ranked #94.

MATAURO first reported a position in NVO in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.61M in Q3 2025. 365 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • MATAURO held 13,144 shares of Novo Nordisk worth $630K as of Q2 2026.
  • MATAURO bought 3,061 Novo Nordisk shares in Q2 2026, an estimated $132K.
  • Novo Nordisk made up 0.08% of MATAURO's portfolio in Q2 2026, its #94 holding.
  • MATAURO first reported a position in Novo Nordisk in Q2 2025 and has held it in 4 quarters since.
  • MATAURO's Novo Nordisk position peaked at $2.61M in Q3 2025.
  • 365 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on MATAURO's 13F filing for Q2 2026, filed 21 Jul 2026.